Clinical trial
Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in…
NCT00374075 · University of Utah, Other · Completed
Key facts
| NCT number | NCT00374075 |
|---|---|
| Title | Study of Safety and Dosing Effect on SMN Levels of Valproic Acid (VPA) in Patients With Spinal Muscular Atrophy |
| Official title | In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy |
| Lead sponsor | University of Utah, Other |
| Collaborators | Families of Spinal Muscular Atrophy Leadiant Biosciences, Inc. Industry Abbott |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Spinal Muscular Atrophy |
| Intervention type | Drug |
| Interventions | Valproic Acid |
| Enrollment | 42 |
| Start date | Sep 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | Sep 8, 2006 |
| Last update posted | May 10, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: